Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Tesomet in Adults and Adolescents with Prader-Willi Syndrome
2021-000127-12Phase 2Terminated
- Sponsor
- Saniona
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Tesomet with Placebo (2 arms). Primary endpoint: Change in total HQ-CT score at Week 16. Started Nov 2021; status: terminated.
02
Drugs
Tesomet
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2021-000127-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000127-12.